Optimized RPE65 promoter and coding sequences
US11969478B2 · kind B2 · utility
0Cited by
2References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 20, 2020 |
| Grant date | Apr 30, 2024 |
| Priority date | — |
| Expiry date | Mar 3, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2830/008
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the prevention and/or treatment of retinal dystrophy in a patient, including Leber congenital amaurosis (LCA).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.